Bharat Biotech International Limited (BBIL) and Bilthoven Biologicals B.V. (BBio) unite forces to amplify the production and security of supply for Oral Polio Vaccines (OPV). This collaborative endeavor is poised to play a pivotal role in advancing global polio eradication initiatives, with a focus on securing regulatory approvals for commercial OPV manufacturing in India and beyond.

In a landmark development heralding a significant stride towards global polio eradication, Bharat Biotech International Limited (BBIL) and Bilthoven Biologicals B.V. (BBio), a subsidiary of Serum Institute of India Private Limited, have announced a groundbreaking collaboration.

The collaboration is strategically designed to bolster the production and security of supply for Oral Polio Vaccines (OPV), with BBIL set to procure essential drug substances from BBio for OPV production. A formal agreement has been inked by representatives from both organizations, underscoring their shared commitment to combatting the menace of polio.

Adar Poonawalla, CEO of Serum Institute of India, expressed his optimism about the partnership, highlighting its pivotal role in advancing the vision of a polio-free world. He emphasized the critical nature of this collaboration in mitigating the impact of polio, a disease that continues to pose significant public health challenges globally.

The collaborative effort aims to navigate the regulatory landscape effectively to obtain all requisite approvals and licenses for commercial OPV manufacturing. This strategic approach underscores a concerted effort to address the global polio burden more effectively and safeguard vulnerable populations against the disease.

Dr. Krishna Ella, Executive Chairman of Bharat Biotech, underscored the importance of oral polio vaccines in India’s Universal Immunization Programme (UIP) and reiterated Bharat Biotech’s commitment to ensuring a secure supply of OPVs. By partnering with BBio, Bharat Biotech aims to reinforce its mission to eradicate polio and contribute meaningfully to global public health.

The alliance between Bharat Biotech and Bilthoven Biologicals represents a significant milestone in the fight against polio, underscoring the power of collaboration in advancing public health agendas and paving the way for a healthier, polio-free future for generations to come.

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Related News